Pregnancy-associated plasma protein-A (PAPP-A) as a possible biomarker in patients with coronary artery disease


Por: Gutiérrez-Leonard H., Martínez-Lara E., Fierro-Macías A.E., Mena-Burciaga V.M., Ronquillo-Sánchez M.D., Floriano-Sánchez E., Cárdenas-Rodríguez N.

Publicada: 1 ene 2017
Categoría: Medicine (miscellaneous)

Resumen:
Background: Cardiovascular disease is the leading cause of death in the Western world, and a major cause of this disease is atherosclerosis. Research has demonstrated that pregnancy-associated plasma protein A (PAPP-A) plays a role in cardiovascular disease, as evidenced by the association between PAPP-A and severity of heart damage. Aim: The aim of this work was to investigate the correlation between PAPP-A concentrations in coronary and peripheral blood and certain clinicopathological factors and antioxidant enzyme activities in patients diagnosed with coronary artery disease. Methods: For 65 patients, arterial blood was obtained by puncturing the femoral or radial artery, and coronary blood was obtained via percutaneous coronary intervention. PAPP-A, catalase (CAT), superoxide dismutase-1 (SOD-1), and superoxide dismutase-2 (SOD-2) levels were measured using spectrometric methods. Results: Coronary PAPP-A levels were slightly higher than peripheral PAPP-A levels (81.25 ± 2.34 and 62 ± 3 ng/mL, respectively, P < 0.0001); these levels were correlated with each other (r = 0.6629, P < 0.001) but not with clinicopathological factors (P > 0.05). Coronary PAPP-A levels were significantly elevated among patients at risk for cardiovascular disease (P < 0.05). Antioxidant enzyme activities were significantly higher in coronary samples than in peripheral samples from subjects with ischemic cardiopathy secondary to atherosclerosis (P < 0.001). Neither coronary nor peripheral PAPP-A levels were correlated with antioxidant enzyme activities in patients with cardiopathy secondary to atherosclerosis (P > 0.05). Conclusions: PAPP-A levels could be used as biomarkers to identify patients at risk of coronary artery disease. © 2016, Royal Academy of Medicine in Ireland.

Filiaciones:
Gutiérrez-Leonard H.:
 Interventional Cardiology Laboratory, Hospital Central Militar, Secretaría de la Defensa Nacional, Mexico City, 11649, Mexico

Martínez-Lara E.:
 Multidisciplinary Research Laboratory, Escuela Militar de Graduados de Sanidad, Secretaría de la Defensa Nacional, Mexico City, 11200, Mexico

Fierro-Macías A.E.:
 Section of Graduate Studies and Research, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, 11340, Mexico

Mena-Burciaga V.M.:
 Section of Graduate Studies and Research, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, 11340, Mexico

Ronquillo-Sánchez M.D.:
 Section of Graduate Studies and Research, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, 11340, Mexico

Floriano-Sánchez E.:
 Multidisciplinary Research Laboratory, Escuela Militar de Graduados de Sanidad, Secretaría de la Defensa Nacional, Mexico City, 11200, Mexico

Cárdenas-Rodríguez N.:
 Laboratory of Neurosciences, Instituto Nacional de Pediatría, Mexico City, 04530, Mexico
ISSN: 00211265
Editorial
Springer International Publishing AG, 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND, Irlanda
Tipo de documento: Article
Volumen: 186 Número: 3
Páginas: 597-605
WOS Id: 000407372800011
ID de PubMed: 27730332